RxDoctor Payments Data

Aneri Patel, MD

Family Medicine · Scottsdale, AZNPI 1053677674

Payments from drug & device makers

$1,567in general payments, 2019–2025

Across 84 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$380
  • Johnson & Johnson$241
  • AbbVie$159
  • AstraZeneca$146
  • Boehringer Ingelheim$89
  • Novo Nordisk$75
  • plus $476 from 14 others

What the payments were for

  • Food & beverage$1,49896%
  • Education$694%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,567 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.

See all family medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$61,895
Medicare patients
229
Services billed
4,224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$29,206
CreonLipase/Protease/Amylase15$17,396
Levothyroxine Sodium311$3,640
SynthroidLevothyroxine Sodium34$3,556
Atorvastatin Calcium309$2,043
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,960
Losartan Potassium157$1,428
Escitalopram Oxalate78$1,184
Rosuvastatin Calcium81$1,117
Celecoxib14$998
ValacyclovirValacyclovir Hcl24$885
Albuterol Sulfate HfaAlbuterol Sulfate30$864
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide39$829
Gabapentin51$819
Duloxetine Hcl33$816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Synthroid$159$20,95249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.

Other family medicine in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →